Luxturna (Voretigene Neparvovec-rzyl)

Number: 0927

Policy

Note: REQUIRES PRECERTIFICATIONFootnote for precertification*

Site of Care Utilization Management Policy applies.  For information on site of service for Luxturna, see Utilization Management Policy on Site of Care for Specialty Drug Infusions

Aetna considers Luxturna (voretigene neparvovec-rzyl) medically necessary for the treatment of individuals with confirmed bi-allelic RPE65 mutation-associated retinal dystrophy when selection criteria are met:

  • Member is at least 12 months of age, but younger than 65 years of age; and
  • Confirmation of bi-allelic pathogenic and/or likely pathogenic RPE65 mutations via genetic testing (single gene test or multi gene panel test if medically necessary); and
  • The RPE65 gene mutations classifications are based on the ACMG standards and guidelines for the interpretation of sequence variants (2015); and
  • Pathogenic and/or likely pathogenic classification of the RPE65 mutations has been affirmed within the last 12 months; and
  • Member has viable retinal cells as determined by optical coherence tomography (OCT) and/or ophthalmoscopy; must have any of the following:
    • an area of retina within the posterior pole of greater than 100 µm thickness shown on OCT;
    • greater than or equal to 3 disc areas of retina without atrophy or pigmentary degeneration within the posterior pole; or
    • remaining visual field within 30 degrees of fixation as measured by a III4e isopter or equivalent.

Aetna considers repeat administration of Luxturna in the same eye experimental and investigational because the effectiveness of this approach has not been established.

Note: Footnote for precertification* Precertification of Luxturna (voretigene neparvovec-rzyl) is required of all Aetna participating providers and members in applicable plan designs.  For precertification of Luxturna (voretigene neparvovec-rzyl), call (866) 503-0857, or fax (866) 267-3277.

Background

Inherited retinal diseases (IRD), also known as inherited retinal dystrophies, are a group of rare blinding conditions caused by 1 of more than 220 different genes; RPE65-related IRD are rare and are caused by mutations in the RPE65 gene.  In the United States, about 1,000 to 2,000 individuals are afflicted with bi-allelic (affecting both copies of a specific gene [on the paternal and maternal chromosomes]) RPE65 mutation-associated IRD.  The RPE65 gene codes for the RPE-specific 65 kDa protein that is needed for the rods and cones to provide normal vision.  Mutations in the RPE65 gene result in reduced or absent levels of RPE65 activity, blocking the visual cycle and leading to impaired vision.  There are several types of RPE65-related IRDs.  The most common are Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP).  Individuals with IRD due to bi-allelic RPE65 gene mutations often experience nyctalopia (night blindness) due to decreased light sensitivity in childhood or early adulthood and nystagmus (involuntary back-and-forth eye movements).  As the disease progresses, individuals may experience loss in their peripheral vision, develope tunnel vision, and eventually, they may lose their central vision as well, resulting in total blindness.  Independent navigation becomes severely limited, and vision-dependent activities of daily living are impaired.  Current investigational therapies for RP include gene therapy, cell therapy, and retinal prostheses.  Gene therapy has the potential to achieve definitive treatment by replacing or silencing a causative gene.  Recently, several clinical trials recently showed significant efficacy of voretigene neparvovec, an ocular gene therapy, for RPE65-mediated IRD.  Voretigene neparvovec works by delivering a normal copy of the RPE65 gene directly to retinal cells, which then produce the normal protein that converts light to an electrical signal in the retina to restore patients’ vision loss.  Voretigene neparvovec uses a naturally occurring adeno-associated virus (AAV), which has been modified using recombinant DNA techniques, as a vehicle to deliver the normal human RPE65 gene to the retinal cells to restore vision. 

Bennett and co-workers (2016) noted that safety and efficacy have been shown in a phase-I, dose-escalation clinical trial involving a unilateral sub-retinal injection of a recombinant AAV vector containing the RPE65 gene (AAV2-hRPE65v2) in individuals with iIRD caused by RPE65 mutations.  This finding, along with the bilateral nature of the disease and intended use in treatment, prompted these researchers to determine the safety of administration of AAV2-hRPE65v2 to the contralateral eye in patients enrolled in the phase-I study.  In this follow-on study, 1 dose of AAV2-hRPE65v2 (1.5 × 1011 vector genomes) in a total volume of 300 μL was sub-retinally injected into the contralateral, previously un-injected, eyes of 11 children and adults (aged 11 to 46 years at 2nd administration) with IRD caused by RPE65 mutations, 1.71 to 4.58 years after the initial sub-retinal injection.  These investigators evaluated safety, immune response, retinal and visual function, functional vision, and activation of the visual cortex from baseline until 3-year follow-up, with observations ongoing.  No adverse events (AEs) related to the AAV were reported, and those related to the procedure were mostly mild including dellen (thinning of the corneal stroma) formation in 3 patients and cataracts in 2.  One patient developed bacterial endophthalmitis and was excluded from analyses.  These researchers noted improvements in efficacy outcomes in most patients without significant immunogenicity.  Compared with baseline, pooled analysis of 10 participants showed improvements in mean mobility and full-field light sensitivity in the injected eye by day 30 that persisted to year 3 (mobility p = 0.0003, white light full-field sensitivity p < 0.0001), but no significant change was seen in the previously injected eyes over the same time period (mobility p = 0.7398, white light full-field sensitivity p = 0.6709).  Changes in visual acuity (VA) from baseline to year 3 were non-significant in pooled analysis in the second eyes or the previously injected eyes (p > 0.49 for all time-points compared with baseline).  The authors concluded that AAV2-hRPE65v2 is the first successful gene therapy administered to the contralateral eye.

In a non-randomized, multi-center, clinical trial, Weleber and associates (2016) provided initial assessment of the safety of a recombinant AAV vector expressing RPE65 (rAAV2-CB-hRPE65) in adults and children with retinal degeneration caused by RPE65 mutations.  A total of 8 adults and 4 children, aged 6 to 39 years, with LCA or severe early-childhood-onset retinal degeneration (SECORD) were included in this analysis.  Patients received a sub-retinal injection of rAAV2-CB-hRPE65 in the poorer-seeing eye, at either of 2 dose levels, and were followed-up for 2 years after treatment.  The primary safety measures were ocular and non-ocular AEs.  Exploratory efficacy measures included changes in best-corrected VA (BCVA), static perimetry central 30° visual field hill of vision (V30) and total visual field hill of vision (VTOT), kinetic perimetry visual field area, and responses to a quality-of-life (QOL) questionnaire.  All patients tolerated sub-retinal injections and there were no treatment-related serious AEs.  Common AEs were those associated with the surgical procedure and included subconjunctival hemorrhage in 8 patients and ocular hyperemia in 5 patients . In the treated eye, BCVA increased in 5 patients, V30 increased in 6 patients, VTOT increased in 5 patients, and kinetic visual field area improved in 3 patients.  One subject showed a decrease in BCVA and 2 patients showed a decrease in kinetic visual field area.  The authors concluded that treatment with rAAV2-CB-hRPE65 was not associated with serious AEs; and improvement in 1 or more measures of visual function was observed in 9 of 12 patients.  The greatest improvements in VA were observed in younger patients with better baseline VA.  They stated that evaluation of more patients and a longer duration of follow-up are needed to determine the rate of uncommon or rare side effects or safety concerns.

In a randomized, controlled, open-label, phase-III clinical trial, Russell and colleagues (2017) evaluated the safety and efficacy of voretigene neparvovec in participants whose IRD would otherwise progress to complete blindness.  This study was carried out at 2 sites in the United States; individuals aged 3 years or older with, in each eye, BCVA of 20/60 or worse, or visual field less than 20 degrees in any meridian, or both, with confirmed genetic diagnosis of bi-allelic RPE65 mutations, sufficient viable retina, and ability to perform standardized multi-luminance mobility testing (MLMT) within the luminance range evaluated, were eligible.  Participants were randomly assigned (2:1) to intervention or control using a permuted block design, stratified by age (less than 10 years; and greater than or equal to 10 years) and baseline mobility testing passing level (pass at greater than or equal to 125 lux versus less than 125 lux).  Graders assessing primary outcome were masked to treatment group.  Intervention was bilateral, sub-retinal injection of 1.5 × 1011 vector genomes of voretigene neparvovec in 0.3 ml total volume.  The primary efficacy end-point was 1-year change in MLMT performance, measuring functional vision at specified light levels.  The intention-to-treat (ITT) and modified ITT (mITT) populations were included in primary and safety analyses.  Between November 15, 2012 and November 21, 2013, a total of 31 individuals were enrolled and randomly assigned to intervention (n = 21) or control (n = 10); 1 subject from each group withdrew after consent, before intervention, leaving an mITT population of 20 intervention and 9 control subjects.  At 1 year, mean bilateral MLMT change score was 1.8 (SD 1.1) light levels in the intervention group versus 0.2 (1.0) in the control group (difference of 1.6, 95 % confidence interval [CI]: 0.72 to 2.41, p = 0.0013); 13 (65 %) of 20 intervention subjects, but no control subjects, passed MLMT at the lowest luminance level tested (1 lux), demonstrating maximum possible improvement.  No product-related serious AEs or deleterious immune responses occurred.  Two intervention participants, one with a pre-existing complex seizure disorder and another who experienced oral surgery complications, had serious AEs unrelated to study participation.  Most ocular events were mild in severity.  The authors concluded that voretigene neparvovec gene therapy improved functional vision in RPE65-mediated IRD previously medically untreatable.

Dias and associates (2017) noted that RP is a hereditary retinopathy that affects about 2.5 million people worldwide.  It is characterized with progressive loss of rods and cones and causes severe visual dysfunction and eventual blindness.  In addition to more than 3,000 genetic mutations from about 70 genes, a wide genetic overlap with other types of IRD has been reported with RP.  This diversity of genetic pathophysiology makes treatment extremely challenging.  These investigators stated that voretigene neparvovec has the potential to achieve definitive treatment by replacing or silencing a causative gene.  They noted that voretigene neparvovec is about to be approved as the first ocular gene therapy.  Despite current limitations such as limited target genes and indicated patients, modest efficacy, and the invasive administration method, development in gene editing technology and novel gene delivery carriers make gene therapy a promising therapeutic modality for RP and other IRD in the future.

On December 19, 2017, the Food and Drug Administration (FDA) approved voretigene neparvovec-rzyl (Luxturna) for the treatment of children and adult patients with confirmed bi-allelic RPE65 mutation-associated retinal dystrophy that leads to vision loss and may cause complete blindness.  To further evaluate the long-term safety, the manufacturer plans to conduct a post-marketing observational study involving patients treated with Luxturna.

The Prescribing Information of Luxturna states that “Use in infants under 12 months of age is not recommended because of potential dilution or loss of Luxturna after administration due to the active retinal cells proliferation occurring in this age group”.  The most common adverse reactions (incidence greater than or equal to 5 %) in the clinical trials were cataract, conjunctival hyperemia, increased intra-ocular pressure, retinal tear, dellen, macular hole, sub-retinal deposits, eye inflammation, eye irritation, eye pain, and maculopathy.

A phase-III clinical trial on “Gene therapy intervention by subretinal administration of AAV2-hRPE65v2 in subjects with Leber congenital amaurosis” provides the following inclusion criteria:

  • Willingness to adhere to protocol and long-term follow-up as evidenced by written informed consent or parental permission and subject assent (where applicable).
  • Diagnosis of LCA due to RPE65 mutations; molecular diagnosis is to be performed, or confirmed, by a CLIA-approved laboratory.
  • Age 3 years old or older.
  • Visual acuity worse than 20/60 (both eyes) and/or visual field less than 20 degrees in any meridian as measured by a III4e isopter or equivalent (both eyes).
  • Sufficient viable retinal cells as determined by non-invasive means, such as optical coherence tomography (OCT) and/or ophthalmoscopy.  Must have either:
    • an area of retina within the posterior pole of greater than 100 µm thickness shown on OCT;
    • greater than or equal to 3 disc areas of retina without atrophy or pigmentary degeneration within the posterior pole; or
    • remaining visual field within 30 degrees of fixation as measured by a III4e isopter or equivalent.
  • Subjects must be evaluable on mobility testing (the primary efficacy end-point) to be eligible for the study.  Evaluable is defined as:
    • The ability to perform mobility testing within the luminance range evaluated in the study.  Individuals must receive an accuracy score of less than or equal to 1 during screening mobility testing at 400 lux or less to be eligible; individuals with an accuracy score of greater than 1 on all screening mobility test runs at 400 lux, or those who refuse to perform mobility testing at screening, will be excluded;
    • The inability to pass mobility testing at 1 lux.  Individuals must fail screening mobility testing at 1 lux to be eligible; individuals that pass one or more screening mobility test runs at 1 lux will be excluded.
According to the Prescribing Information (Spark Therapeutics, 2017), Luxturna for subretinal injection occurs after completing a vitrectomy. The subretinal injection cannula can be introduced via pars plana. Thus, the subretinal injection of Luxturna requires a pars plana vitrectomy.  

ACMG Standards and Guidelines:

The American College of Medical Genetics and Genomics (ACMG) is a specialty society that develop and sustain genetic and genomic initiatives in clinical and laboratory practice, education, and advocacy. The ACMG have created a standards and guidelines report for the classification and interpretation of sequence variants, which includes defined terms for variant classification guidance. For instance, the term "mutation" is defined as a permanent change in the nucleotide sequence, whereas polymorphism is defined as a variant with a frequency above 1%. ACMG notes these terms often lead to confusion because of incorrect assumptions of pathogenic and benign effects. Therefore, ACMG recommends replacing those terms for the use of specific standard terminology—“pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”. Furthermore, the recommendations describe a process for classifying variants into these five categories based on criteria using typical types of variant evidence (e.g., population data, computational data, functional data, segregation data). These recommendations primarily apply to the breadth of genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Due to the increased complexity of analysis and interpretation of clinical genetic testing described in the ACMG Standards and Guidelines report, the ACMG strongly recommends that clinical molecular genetic testing be performed in a Clinical Laboratory Improvement Amendments–approved laboratory, with results interpreted by a board-certified clinical molecular geneticist or molecular genetic pathologist or the equivalent (Richards et al, 2015). See ACMG Standards and Guidelines for the Interpretation of Sequence Variants

Appendix

Dosing Information:

  • The recommended dose of Luxturna for each eye is 1.5 x 1011 vector genomes (vg), administered by sub-retinal injection in a total volume of 0.3 ml.
  • Perform sub-retinal administration of Luxturna to each eye on separate days within a close interval, but no fewer than 6 days apart.
  • Recommend systemic oral corticosteroids equivalent to prednisone at 1 mg/kg/day (maximum of 40 mg/day) for a total of 7 days (starting 3 days before administration of Luxturna to each eye), and followed by a tapering dose during the next 10 days.

Table: CPT Codes / HCPCS Codes / ICD-10 Codes
Code Code Description

Information in the [brackets] below has been added for clarification purposes.   Codes requiring a 7th character are represented by "+" :

Other CPT codes related to the CPB:

67028 Intravitreal injection of a pharmacologic agent (separate procedure)
67036 Virectomy, mechanical, pars plana approach
67039     with focal endolaser photoconagulation
67040     with endolaser panretinal photocoagulation
67041     with removal of preretinal cellular membrane (eg, macular pucker)
67042     with removal of internal limiting membrane of retina (eg, for repair of macular hole, diabetic macular edema), includes, if performed, intraocular tamponade (ie, air, gas or silicone oil)
67043     with removal of subretinal membrane (eg, choroidal neovascularization), includes, if performed, intraocular tamponade (ie, air, gas, or silicone oil) and laser photocoagulation
81406 Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia)
81434 Hereditary retinal disorders (eg, retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy), genomic sequence analysis panel, must include sequencing of at least 15 genes, including ABCA4, CNGA1, CRB1, EYS, PDE6A, PDE6B, PRPF31, PRPH2, RDH12, RHO, RP1, RP2, RPE65, RPGR, and USH2A
92134 Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina
92225 Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report, initial

HCPCS codes covered if selection criteria are met:

C9032 Injection, voretigene neparvovec-rzyl, 1 billion vector genome

ICD-10 codes covered if selection criteria are met:

H35.50 Unspecified hereditary retinal dystrophy [bi-allelic RPE65 mutation-associated retinal dystrophy]

The above policy is based on the following references:

  1. Bennett J, Wellman J, Marshall KA, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: A follow-on phase 1 trial. Lancet. 2016;388(10045):661-672.
  2. Weleber RG, Pennesi ME, Wilson DJ, et al. Results at 2 years after gene therapy for RPE65-deficient Leber congenital amaurosis and severe early-childhood-onset retinal dystrophy. Ophthalmology. 2016;123(7):1606-1620.
  3. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849-860.
  4. Food and Drug Administration. FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. FDA: Silver Spring, MD. December 19, 2017. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm589467.htm. Accessed January 2, 2018.
  5. No authors listed. Highlights of Prescribing Information. Luxturna (voretigene neparvovec-rzyl) intraocular suspension for sub-retinal injection. Spark Therapeutics, Inc. Philadelphia, PA. 2017.  Available at: https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM589541.pdf. Accessed January 2, 2018.
  6. National Institutes of Health. Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis. ClinicalTrials.gov. Last updated March 28, 2017. Available at:  https://clinicaltrials.gov/show/NCT00999609. Accessed January 5, 2018.
  7. Dias MF, Joo K, Kemp JA, et al. Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives. Prog Retin Eye Res. 2018;63:107-131.
  8. Richards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee.. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24.
  9. Spark Therapeutics, Inc. Luxturna (voretigene neparvovec-rzyl) intraocular suspension for subretinal injection. Prescribing Information. Philadelphia, PA: Spark; 2017.